

Amendments to the Claims


This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A method to normalize the contractile response of ~~an endothelial~~
~~compromised vascular smooth muscle cell in response to a vasoconstrictor agonist~~
~~vasculature~~ in a patient in need of such normalization, ~~the vasculature comprising a vascular~~
~~smooth muscle cell layer and a compromised endothelial cell layer, wherein the method~~
~~comprising~~ ~~comprises~~ administering a pharmaceutically effective amount of a CLC3 blocker,
or a pharmaceutically acceptable salt thereof.
- 2-5. (Cancelled)
6. (Previously Presented) A method of claim 23, wherein the compound administered is 1-p- β -
dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable
salt thereof.
7. (Previously presented) A method of claim 23, wherein the patient has diabetes.
8. (Previously presented) A method of claim 23, wherein the patient has had a surgical
procedure.
9. (Previously presented) A method of claim 23, wherein the patient has hypertension.
10. (Previously presented) A method of claim 23, wherein the patient has coronary artery
disease.
11. (Previously presented) A method of claim 23, which further comprises administering a
pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes
agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-
restenosis agent.

12-22. (Cancelled)

23. (Previously presented) A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R⁴ is H or a lower alkyl radical and R⁵ is a lower alkyl radical, or R⁴ and R⁵ are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R⁶ is H or a lower alkyl radical;

R⁷ is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R⁸ is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. (Cancelled)

25. (Currently Amended) A method to normalize the contractile response of an endothelially compromised vascular smooth muscle cell vasculature in response to a vasoconstrictor agonist in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method

Applicant : Fred S. Lamb
Serial No. : 09/512,926
Filed : February 25, 2000
Page : 4 of 10

Attorney's Docket No.: 17023-010001 / N9-19

comprising comprises administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof, and wherein the vasoconstrictor agonist is norepinephrine, KCl or serotonin.